Document Detail


Apixaban. After hip or knee replacement: LMWH remains the standard treatment.
MedLine Citation:
PMID:  23016247     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
The standard anticoagulant for prevention of venous thromboembolism in patients undergoing hip or knee replacement surgery is a low-molecular-weight heparin (LMWH) such as subcutaneous enoxaparin. Apixaban is the second oral factor Xa inhibitor, after rivaroxaban, to be approved in the European Union for use in these two situations. Three double-blind randomised trials versus enoxaparin in a total of nearly 12 000 patients failed to show that apixaban was more effective in terms of relevant endpoints: mortality, and the incidence of pulmonary embolism and symptomatic deep vein thrombosis. The incidence of bleeding did not differ between the apixaban and enoxaparin groups under the conditions of these trials. Apixaban is mainly metabolised by cytochrome P450 isoenzymes CYP 3A4 and 3A5 and also binds to P-glycoprotein, resulting in a high potential for pharmacokinetic interactions. Renal failure is a risk factor for overdose. Pharmacodynamic interactions are also likely. There is no known antidote for apixaban. In practice, LMWH remains the standard treatment.
Authors:
-
Related Documents :
23919217 - Association of itpa polymorphism with outcomes of peginterferon-α plus ribavirin combi...
23371327 - Weekly teriparatide injections successfully treated advanced bisphosphonate-related ost...
18807057 - Long-term outcomes after tympanoplasty with and without mastoidectomy for perforated ch...
24130347 - Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis. a ran...
7803737 - Respiratory function after cardiopulmonary bypass: a comparison of bubble and membrane ...
18206917 - Predictors of treatment failure 24 months after surgery for stress urinary incontinence.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Prescrire international     Volume:  21     ISSN:  1167-7422     ISO Abbreviation:  Prescrire Int     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-09-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9439295     Medline TA:  Prescrire Int     Country:  France    
Other Details:
Languages:  eng     Pagination:  201-2, 204     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of case management in an era of healthcare reform--Part 3.
Next Document:  Denosumab and bone metastases. No better than a bisphosphonate.